FRANCES SWARN: Open Payments
NPI 1508983537 · MANSFIELD, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$481 in 24 payments from 10 companies in 2025. Trend: 2023 $36 · 2024 $26 · 2025 $481
Food & beverage: $481
| Company | Payments | Amount |
|---|---|---|
| Luye Pharma (USA) Ltd. | 4 | $89 |
| Neurocrine BioSciences, Inc. | 4 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| ABBVIE INC. | 1 | $32 |
| E.R. Squibb & Sons, L.L.C. | 2 | $29 |
| Alkermes, Inc. | 2 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
Products named: ERZOFRI EXTENDED-RELEASE, INGREZZA, CAPLYTA, ABILIFY MAINTENA, Auvelity, VRAYLAR, COBENFY, ARISTADA.
Industry payments across OH — which companies pay providers there.
